P.O. Box 3660, Riyadh 11481, Mail Code 1515 (KAIMRC)
+966 (11) 429-4444
+966 (11) 429-4440

Publication Details

Title :

A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.

Journal:

J Infect Dis.

Impact Factor:

5.186

Authors:

Hashem AM1,2,3, Algaissi A4,5, Agrawal AS4, Al-Amri SS2,3, Alhabbab RY2,3,6, Sohrab SS3, S Almasoud A7, Alharbi NK7, Peng BH8, Russell M9, Li X9, Tseng CK4,10.

Affiliations:

1 Department of Medical Microbiology and Parasitology, Faculty of Medicine.

2 Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, Saudi Arabia.

3 Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

4 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston.

5 Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University.

6 Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah.

7 Department of Infectious Disease Research, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

8 Department of Neurosciences, Cell Biology, and Anatomy, University of Texas Medical Branch, Galveston.

9 Center for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ontario.

10 Center of Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston.

Year of Publication:

2019

DOI:

10.1093/infdis/jiz137.

Abstract:

BACKGROUND:
Infection control measures have played a major role in limiting human/camel-to-human transmission of Middle East respiratory syndrome coronavirus (MERS-CoV); however, development of effective and safe human or camel vaccines is warranted.

METHODS:
We extended and optimized our previous recombinant adenovirus 5 (rAd5)-based vaccine platform characterized by in vivo amplified and CD40-mediated specific responses to generate MERS-CoV S1 subunit-based vaccine. We generated rAd5 constructs expressing CD40-targeted S1 fusion protein (rAd5-S1/F/CD40L), untargeted S1 (rAd5-S1), and Green Fluorescent Protein (rAd5-GFP), and evaluated their efficacy and safety in human dipeptidyl peptidase 4 transgenic (hDPP4 Tg+) mice.

RESULTS:
Immunization of hDPP4 Tg+ mice with a single dose of rAd5-S1/F/CD40L elicited as robust and significant specific immunoglobulin G and neutralizing antibodies as those induced with 2 doses of rAd5-S1. After MERS-CoV challenge, both vaccines conferred complete protection against morbidity and mortality, as evidenced by significantly undetectable/reduced pulmonary viral loads compared to the control group. However, rAd5-S1- but not rAd5-S1/F/CD40L-immunized mice exhibited marked pulmonary perivascular hemorrhage post-MERS-CoV challenge despite the observed protection.

CONCLUSIONS:
Incorporation of CD40L into rAd5-based MERS-CoV S1 vaccine targeting molecule and molecular adjuvants not only enhances immunogenicity and efficacy but also prevents inadvertent pulmonary pathology after viral challenge, thereby offering a promising strategy to enhance safety and potency of vaccines.